A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2016-05-24
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- Celularity Incorporated
- Target Recruit Count
- 10
- Registration Number
- NCT02781467
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Myelodysplastic SyndromesLeukemia, Myeloid, Acute
- Interventions
- Biological: Durvalumab
- First Posted Date
- 2016-05-18
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 213
- Registration Number
- NCT02775903
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸University of Florida, Gainesville, Florida, United States
Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101)
- Conditions
- LeukemiaAcute Myelogenous LeukemiaAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2016-05-16
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 11
- Registration Number
- NCT02773732
- Locations
- 🇺🇸
UF Health Shands Cancer Hospital, Gainesville, Florida, United States
A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
- Conditions
- Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
- Interventions
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 183
- Registration Number
- NCT02752035
- Locations
- 🇺🇸
UCLA David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸University of California, Irvine Medical Center, Orange, California, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- Conditions
- Chronic Myelomonocytic Leukemia (CMML)Myelodysplastic Syndrome (MDS)Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2019-04-22
- Target Recruit Count
- 13
- Registration Number
- NCT02749708
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 62
- Registration Number
- NCT02715011
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Celgene
- Target Recruit Count
- 130
- Registration Number
- NCT02677922
- Locations
- 🇺🇸
Local Institution - 105, Duarte, California, United States
🇺🇸Local Institution - 107, New Haven, Connecticut, United States
🇺🇸Local Institution - 108, Chicago, Illinois, United States
Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid LeukemiaLeukemia
- Interventions
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 539
- Registration Number
- NCT02668653
- Locations
- 🇺🇸
University of Florida (UF) Health Shands Hospital, Gainesville, Florida, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Franciscan St. Francis Health Indianapolis, Indianapolis, Indiana, United States
Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia With Multilineage DysplasiaMyeloid SarcomaSecondary Acute Myeloid LeukemiaTherapy-Related Acute Myeloid LeukemiaTherapy-Related Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2016-01-18
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT02658487
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants with Relapsed/Refractory Cancer Indications
- Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)Metastatic Colorectal Cancer (mCRC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)Higher-Risk Myelodysplastic Syndrome (HR-MDS)Newly Diagnosed Intermediate/High-Risk MDSAcute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 277
- Registration Number
- NCT02649790
- Locations
- 🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸Oncology Institute of Hope and Innovation, Pasadena, California, United States
🇺🇸Rocky Mountain Regional VA Medical Center, Aurora, Colorado, United States